Emcure Pharmaceuticals Limited has made a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding a change in senior management personnel.
Nature of Event: Cessation of senior management personnel due to superannuation.
Key Personnel Change: Mr. Kuber Jagdale, President – API Business, has superannuated from his employment with the Company. The cessation took effect from close of business hours on June 30, 2026. Consequently, he ceases to be a Senior Management Personnel as per Regulation 16(1)(d) of the SEBI Listing Regulations.
Reason for Cessation: Superannuation (retirement). The company specifically notes that this cessation does not constitute a resignation, and therefore submission of a resignation letter is not applicable.
Regulatory Compliance: The disclosure is made pursuant to Regulation 30 and includes the particulars required under Part A of Schedule III of the SEBI Listing Regulations, which are provided in Annexure A.
Annexure A Details:
- Reason for change: Superannuation
- Date of cessation: Close of business hours on June 30, 2026
- Brief profile: Not Applicable
- Disclosure of relationships between Directors: Not Applicable
Document References:
- Reference Number: EPL/CS/SE/0053/2026
- Date of signing: June 30, 2026 at 17:32:41 IST
Financial Impact: No financial impact disclosed.
Operational Impact: The change represents a routine senior management transition due to retirement, with no indication of operational disruption mentioned.